

17th Congress of the European Association for Clinical Pharmacology and Therapeutics

Embracing Innovations for Optimized Patient Care

28 June - 1 July 2025 Helsinki, Finland





Welcome to EACPT2025

Dear colleagues,

On behalf of the Finnish Society of Clinical Pharmacology, the European Society of Clinical Pharmacology and the Local Organizing Committee, it is our great pleasure to welcome you to the 17th Congress of the European Association for Clinical Pharmacology and Therapeutics in Helsinki, Finland, 28 June – 1 July 2025.

The 17th EACPT Congress is part of a very successful series of regular congresses that the EACPT started 30 years ago with the first congress in Paris in 1995. The theme of the 2025 Congress is "Embracing Innovations for Optimized Patient Care". Accordingly, the congress will explore the latest advancements in clinical pharmacology and therapeutics, covering novel issues related to clinical pharmacology in healthcare and teaching, drug development, research and regulation, as well as new and emerging therapies.

Helsinki in late June offers typically very friendly weather conditions and extended daylight hours, providing you a unique chance to experience the Nordic "midnight sun." Enjoy mild temperatures and the beautiful ambience as the city bathes in natural light well into the evening.

We look forward to welcoming you to an unforgettable gathering under the welcoming skies of Helsinki!

Sincerely yours,

Professor Janne T. Backman Chair of EACPT2025 Helsinki









Committees

EACPT2025 Local Organizing Committee

Janne T. Backman, University of Helsinki (Chair)
Mikko Niemi, University of Helsinki (Co-Chair)
Mikko Airavaara, University of Helsinki
Laura Aurinsalo, University of Helsinki
Maija Kaukonen, Medbase Ltd
Mikko Koskinen, Orion Pharma
Noora Kulla, University of Turku
Outi Lapatto-Reiniluoto, Helsinki University Hospital
Eeva Moilanen, Tampere University
Jukka Mäenpää, AstraZeneca
Aleksi Tornio, University of Turku
Miia Turpeinen, University of Oulu
Piia Vuorela, Finnish Medicines Agency
Petri Mäkelä, University of Helsinki (secretary)

Other Local Working Group members

Piia Aarnisalo, Pfizer
Pauliina Ehlers, Pharma Industry Finland
Päivi Hirvensalo, University of Turku
Risto Huupponen,† University of Turku
Taavi Kaartinen, University of Helsinki
Ville Kainu, Pfizer
Minna Lehtisalo, University of Helsinki
Anssi Mykkänen, University of Helsinki
Mikael Piha, University of Turku
Kirsti Villikka, Finnish Medicines Agency

EACPT Executive Committee

Gerard Rongen, The Netherlands (Chairperson) Janne T. Backman, Finland (Chairperson-elect) Joaquín Sáez Peñataro, Spain (Secretary) Julia Stingl, Germany (Treasurer) Pierre Marquet, France (Past-Chairperson) Annalisa Capuano, Italy Thomas Griesbacher, Austria Florian Naudet, France Dinko Vitezic, Croatia Caridad Pontes, Spain Ivana Kacirova, Czech Republic Dominique Deplanque, France David Williams, Ireland Michiel van Agtmael, The Netherlands Emilie Jouanjus, France Carla Sans Pola, Spain Concepción Payares, Spain

EACPT2025 Scientific Advisory Committee


Michiel van Agtmael, Netherlands Troels K. Bergmann, Denmark Jérôme Bonzon, Switzerland Marja-Liisa Dahl, Sweden Ann Daly, United Kingdom Jan De Hoon, Belgium Dominique Deplanque, France Erik Eliasson, Sweden Anne Filppula, Finland Martin Fromm, Germany Piet van der Graaf, Netherlands Thomas Griesbacher, Austria Katri Hämeen-Anttila, Finland In-Jin Jang, Korea Asko Järvinen, Finland Annikka Kalliokoski, Finland Raisa Laaksonen, Finland Kari Laine, Finland Lasse Lehtonen, Finland Sammeli Liikkanen, Finland M Isabel Lucena, Spain Pierre Marquet, France Timo Myöhänen, Finland Florian Naudet, France Clive Page, United Kingdom Andreas Papapetropoulos, Greece Joost Piët, Netherlands Caridad Pontes, Spain Gerard Rongen, Netherlands Joaquin Sáez Peñataro, Spain Carolina Säll, Denmark Caroline Samer, Switzerland Maria Jesus Sanz, Spain Eriika Savontaus, Finland Ulf Simonsen, Denmark Julia Stingl, Germany Virpi Talman, Finland Olli Tenhunen, Finland Dinko Vitezic, Croatia Katriina Vuolteenaho, Finland Lauren Walker, United Kingdom Markus Zeitlinger, Austria

Congress Secretariat

Confedent international Riikka Louhivuori eacpt2025@confedent.fi



Program at a glance



Basic & Clinical Pharmacology & Toxicology

Why publish in BCPT?

- Nordic journal in pharmacology and toxicology with global view
- Dedicated scientists committed to sharing high-quality pharmacology and toxicology research
- Revenue reinvested in the scientific community to advance medicine and reduce patient harm

Scan to learn more





Editor-in-Chief Jens Lykkesfeldt



Editor-in-Chief **Ulf Simonsen**



Full program SATURDAY, 28 JUNE

16:00-19:00 Early-career researchers' premeeting

Venue: Solo Sokos Hotel Helsinki, Blomstedt Hall, Kluuvikatu 8, Helsinki, Finland

Chairs: Laura Aurinsalo, University of Helsinki, Helsinki, Finland and Mikael Piha, University of Turku, Turku, Finland

16:00 - 16:10 | Welcome remarks

16:00 - 16:05 **Welcome remarks**

Chair of the premeeting organizing committee Laura Aurinsalo, University of Helsinki, Helsinki,

Chair of the EACPT2025 organizing committee Janne Backman, University of Helsinki, Helsinki, Finland

Chairman of the EACPT Executive committee Gerard Rongen, Radboud University, Nijmegen, the Netherlands

16:05 - 16:10 **Sponsor's presentation**

Editor-in-Chief Jens Lykkesfeldt, Basic & Clinical Pharmacology & Toxicology

16:10 - 16:55 | Career paths in Clinical Pharmacology

16:10 - 16:25 How to create a successful career in the academia and regulatory agencies?

Julia Stingl, University Hospital Heidelberg, Heidelberg, Germany

16:25 - 16:40 How to pursue a career in the pharmaceutical industry?

Silke Simon, Roche, Basel, Switzerland

16:40 - 16:55 Transforming academic research into a (successful) biotech start-up

Christoffer Clemmensen, University of Copenhagen and Ousia Pharma, Copenhagen, Denmark

16:55 - 17:25 | Panel discussion on career paths in clinical pharmacology & questions

Julia Stingl, University Hospital Heidelberg, Heidelberg, Germany Christoffer Clemmensen, University of Copenhagen and Ousia Pharma, Copenhagen, Denmark Silke Simon, Roche, Basel, Switzerland

17:30 - 18:10 | Coffee break and group work

18:10 - 18:40 | Group work presentations

17:25 - 17:30 | Group work instructions

18:40 - 18:45 | EACPT Communication working group activities

Marc Labriffe, University of Limoges, Limoges, France

18:45 - 18:55 | EACPT early-career working group updates

Andrej Belančić, University of Rijeka, Rijeka, Croatia Laura Aurinsalo, University of Helsinki, Helsinki, Finland

18:55 - 19:00 | Final remarks

19:00 - 20:00 | Congress registration and group photo

20:00 - 23:00 | Premeeting dinner



SUNDAY, 29 JUNE

9:00 - 9:15 | Opening Welcome Remarks (Great Hall)

Welcome Remarks

EACPT2025 Chair Janne Backman, University of Helsinki, Helsinki, Finland, and EACPT Chairperson Gerard Rongen, University of Nijmegen, Nijmegen, the Netherlands

9:20 - 10:00 | Keynote Lecture 1 (Great Hall)

Chair: Janne Backman, University of Helsinki, Helsinki, Finland

The role of the European Medicines Agency in advancing science and innovation in Europe Steffen Thirstrup, Chief Medical Officer, European Medicines Agency

10:00 - 10:30 | Refreshment Break (Catering areas on 1st and 2nd floor)

10:30 - 12:00 | Concurrent Sessions

Awards session (EPHAR/EACPT) (Great Hall)

Co-Chairs: EACPT Chairperson Gerard Rongen, University of Nijmegen, Nijmegen, the Netherlands, EPHAR Chairperson Maria Jesus Sanz, University of Valencia, Valencia, Spain, and FSCP Chair Mikko Niemi, University of Helsinki, Helsinki, Finland

In this session, we will announce the recipients of the Joint EPHAR-EACPT Young Investigator Awards in Pharmacology 2025, followed by presentations from the awardees. Additionally, the Finnish Society of Clinical Pharmacology will present its awards and recognitions, including a presentation by the Best PhD Thesis 2024 awardee.

10:30 - 11:00	Joint EPHAR-EACPT Young Investigator Award in Pharmacology 2025; EPHAR Award
	presentation
11:00 - 11:30	Joint EPHAR-EACPT Young Investigator Award in Pharmacology 2025 ; EACPT Award presentation
11:30 - 12:00	Finnish Society of Clinical Pharmacology (FSCP) Awards and recognitions

Session B1: Preclinical data informing clinical pharmacology (Small Hall)

Chairs: Mikko Koskinen, Orion Corporation, Espoo, Finland and Piet van der Graaf, Certara, Canterbury, United Kingdom

0	
10:30 - 11:00	QSP modelling - Speeding dose escalation trials in immuno-oncology Piet van der Graaf, Certara, Canterbury, United Kingdom
11:00 - 11:30	Translational PKPD informing clinical dose selection Pablo Morentin Gutierrez, AstraZeneca, Cambridge, United Kingdom
11:30 - 11:45	Identifying Parkinson's disease-associated genes via a genome-wide association study of Taiwanese population and a cell model (Abstract 0001) Ping Lin Tsai, National Cheng Kung University, Tainan, Taiwan
11:45 - 12:00	In vivo assessment of MRP1 activity in murine and human skeletal muscle (Abstract O002) Matthias Jackwerth, Medical University of Vienna, Vienna, Austria

Session C1: Therapeutic advances in the treatment of obesity (Auditorium)

Chairs: Eriika Savontaus, University of Turku, Turku, Finland and Dominique Deplanque, University of Lille, Lille, France

10:30 - 11:00	Next generation anti-obesity drugs Christoffer Clemmensen, University of Copenhagen, Copenhagen, Denmark
11:00 - 11:30	Pharmacovigilance of anti-obesity drugs Jean-Luc Faillie, CHU de Montpellier, Montpellier, France
11:30 - 11:45	Lingonberry supplementation induces anti-obesity and health-promoting effects on gut microbiome in high-fat diet-induced experimental obesity (Abstract 0003) liro Piippo, Tampere University, Tampere, Finland
11:45 - 12:00	Effect of methylphenidate on BMI in children in relation to weight status (Abstract 0004) Jenny Kindblom, Sahlarenska University Hospital, Gothenburg, Sweden



12:00 - 14:00 | Lunch and Poster Viewing Lunch (Catering areas in 1st and 2nd floor) Posters and Coffee (Poster areas 1st to 4th floor) 12:30 - 14:00 Trainee poster award nominees (posters A101-A120) 12:30 - 13:15 Nominee presentations to Awards Committee 13:15 - 14:00 Presenters at posters 13:00 - 14:00 Presenters at posters P201-P220, P301-P324, P401-413 14:00 - 15:30 | Concurrent Sessions Session A1: Multiprofessional approach to pharmacotherapy (Auditorium) Chairs: Lasse Lehtonen, Helsinki University Hospital, Helsinki, Finland and Raisa Laaksonen, University of Helsinki, Helsinki, Finland 14:00 - 14:30 Importance of clinical pharmacological and pharmaceutical care for medication safety with oral antitumor therapy Martin Fromm, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany Minimizing the risks in pharmacotherapy with medication review 14:30 - 15:00 Eva Sædder, Aarhus University Hospital, Denmark The tailored youngAMBORA care program during pediatric oral antitumor therapy solves 15:00 - 15:15 medication errors and improves satisfaction with information (Abstract 0005) Phyllis Lensker, Institute of Experimental and Clinical Pharmacology and Toxicology, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany 15:15 - 15:30 Drug-related problems from the pharmaceutical care perspective and the healthcare perspective: an explorative analysis (Abstract 0006) Per Thysell, Sahlgrenska University Hospital, Gothenburg, Sweden Session B2: Artificial intelligence in drug development (Great Hall) Chairs: Sammeli Liikkanen, Orion Corporation, Turku, Finland and Lauren Walker, University of Liverpool, Liverpool, United Kingdom 14:00 - 14:30 Use of AI in the medication safety field Lauren Walker, University of Liverpool, Liverpool, United Kingdom 14:30 - 15:00 Al to reveal hidden biological mechanisms of disease and discover breakthrough drugs by digital twins Bruce Church, Aitia, Cambridge, Massachusetts, United States Drug-induced changes in gastrointestinal pacemaker activity may predict drug adverse 15:00 - 15:15 reactions beyond the gut using a deep learning approach (Abstract 0007) Yuen Hang LIU, The Chinese University of Hong Kong, Hong Kong, Hong Kong 15:15 - 15:30 How well can current decision support systems predict adverse drug events and can predicts be improved using machine learning? (Abstract 0008) Marine L. Andersson, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden Session C2: Immunopharmacology (Small Hall) Chairs: Eeva Moilanen, Tampere University, Tampere, Finland and Ulf Simonsen, Aarhus University, Aarhus, Denmark 14:00 - 14:30 Glucocorticoids: Novel insights into mechanisms Karolien De Bosscher, UGent Department of Biomolecular Medicine, Ghent, Belgium Transient Receptor Potential (TRP) ion channels: Novel TRPA1 inhibitor for chronic pain. 14:30 - 15:00 Preclinical and phase I clinical results Zsuzsanna Helves, Department of Pharmacology and Pharmacotherapy, Medical School, University of Pécs, Pécs, Hungary Effect of severe renal function impairment on the single-dose pharmacokinetics, 15:00 - 15:15 pharmacodynamics, safety, and tolerability of cenerimod (Abstract 0009) Markus Stefan Mueller, Viatris Innovation GmbH, Allschwil, Switzerland The contact allergen methylisothiazolinone (MIT) is a potent activator of the TRPA1 ion 15:15 - 15:30 channel (Abstract 0010) llari Mäki-Opas, Tampere University, Tampere, Finland

15:30 - 16:00 | Refreshment Break (Catering areas on 1st and 2nd floor)



16:00 - 18:00 | Concurrent Sessions

Session A2: Education symposium 'Education pearls in CPT' (Small Hall)

Chairs: Michiel van Agtmael, Amsterdam University Medical Center, Amsterdam, the Netherlands and Eriika Savontaus, University of Turku, Turku, Finland

16:00 - 16:15	Team-based learning Jitka Rychlíčková, Masaryk University, Brno, Czech Republic
16:15 - 16:30	OSCE Ellen van Leeuwen, Ghent University, Ghent, Belgium
16:30 - 16:45	Multiprofessional education Karen Keijsers, Jeroen Bosch Hospital, Den Bosch, The Netherlands
16:45 - 17:00	Flipped classroom Emilio Sanz, Universidad de La Laguna, La Laguna, Spain
17:00 - 17:40	Simulating prescribing in an acute situation Students, Finland (coached by David Brinkman)
17:40 - 17:45	Educational virtual escape room Ullamari Pesonen, University of Turku, Turku, Finland
17:45 - 18:00	Development of a drug list based on mechanisms of action and INN nomenclature for undergraduate medical training (Abstract 0011) Alexander Oksche, Impp, Mainz, Germany

SSCPT Session B3: Cardiac toxicity (Auditorium)

Chairs: Caroline Samer, Hôpitaux Universitaires de Genève, Geneva, Switzerland and Jérôme Bonzon, University Hospital Zurich, Zurich, Switzerland

Troophal Zollett, Zollett, Gwilzollaria		
16:00 - 16:25	Clinical aspects of cardiotoxicity in the development of new drugs Martin Bucher, University Hospital Zurich, Zurich, Switzerland	
16:25 - 16:50	The broad spectrum of drug induced cardiotoxicities François Girardin, CHUV, Centre hospitalier universitaire Vaudois, Lausanne, Switzerland	
16:50 - 17:15	Epigenetic Rewiring in Doxorubicin-Induced Endotheliopathy Shafeeq A. Mohammed, University of Zurich, Zurich, Switzerland	
17:15 - 17:30	Pharmacogenomics in prediction of cardiovascular drugs' adverse reaction (PGx-CardioDrug) – data after 4 years (Abstract O012) Livija Šimičević, University of Zagreb School of Medicine, Zagreb, Croatia	

Industry Sponsored Talk by Celerion (Auditorium)

17:30 - 18:00	To waive or not to waive; Cardiac liability assessments in early drug development
	Robert Lester, Celerion, Tempe, Arizona, United States
	Caroline Engel, Celerion, Montreal, Quebec, Canada

EPHAR Session C3: RNA therapeutics (Great Hall)

Chairs: Maria Jesus Sanz, University of Valencia, Valencia, Spain and Andreas Papapetropoulos, National and Kapodistrian University of Athens, Athens, Greece

Rapodisiliali offi	veisity of Ameris, Ameris, Orecee
16:00 - 16:30	RNA therapeutics from theory to practice: an overview of mechanisms and approved drugs Andreas Papapetropoulos, National and Kapodistrian University of Athens, Athens, Greece
16:30 - 17:00	Lessons from the development of miR125b*and miR450a for cardioprotection Peter Ferdinandy, Semmelweis University, Budapest, Hungary
17:00 - 17:30	We are formulators, how may we help? Lea Ann Dailey, University of Vienna, Vienna, Austria
17:30 - 17:45	Towards the fine understanding of local pharmacokinetics adopting integrative multiscale strategy (Abstract O014) Florent Di Meo, Inserm U1248 P&t, Univ. Limoges, Limoges, France

18:00 - 18:30 | Exhibition Break (Exhibition Hall Agora)

18:30 - 19:15 | EACPT Lifetime Achievement Award and Lecture (Great Hall)

Chair: EACPT Past-Chairman Pierre Marquet, University of Limoges, Limoges, France In this session, we will announce the recipient of the 2025 EACPT Lifetime Achievement Award, followed by a presentation by the awardee.



19:15 - 20:00 | Opening ceremony (Great Hall)

Chair: EACPT2025 Chair Janne Backman, University of Helsinki, Helsinki, Finland

- Opening remarks by Janne Backman, Congress Chair
- Address by Laura Rissanen, State Secretary, Ministry of Social Affairs and Health, Finnish Government
- Greetings by Mikko Niemi, President of the Finnish Society of Clinical Pharmacology
- Music Performance
- Welcome Address by Kai Nordlund, Vice Rector, University of Helsinki

20:00 - 21:00 | Reception (Great Hall Foyers)

Small snacks available at the reception.

21:00 - 23:00 | Social event at Allas Pool (separate ticket required)



MONDAY, 30 June

6:40 - 7:40 | EACPT Run and early morning activities (Fabianinkatu 20 or Senate Square)

Participate with colleagues in the EACPT walk, run or yoga and get an energy boost for the second congress day

8:20 - 9:00 | Keynote Lecture 2 (Great Hall)

Chair: Outi Lapatto-Reiniluoto, Helsinki University Hospital, Helsinki, Finland

Climate change and its health dimensions

Petteri Taalas, Director General, Finnish Meteorological Institute

9:00 - 10:30 | Concurrent Sessions

Session A3: Societal perspective of pharmacotherapy (Great Hall)

Chairs: Katri Hämeen-Anttila, University of Eastern Finland, Kuopio, Finland and Martin Fromm, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany

9:00 - 9:30	Policies and strategies to enhance uptake of biosimilars Dorthe Bartels, Amgros I/S, Copenhagen, Denmark
9:30 - 10:00	Financial burden of medicines for patients Katri Aaltonen, University of Turku, Turku, Finland
10:00 - 10:15	Increasing use of gabapentinoids out of their authorised indications (Abstract 0015) Caridad Pontes, Hospital De La Santa Creu I Sant Pau - Universitat Autònoma De Barcelona, Barcelona, Spain
10:15 - 10:30	Polypharmacy in old patients before and after acute rehabilitation – an observational study in Western Pomerania (Abstract 0016) Benedikt Eisenmann, University Greifswald, Departement of Clinical Pharmacology, Greifswald, Germany

Session B4: Drug development beyond the era of small molecules (Auditorium)

Chairs: Katriina Vuolteenaho, Tampere University, Tampere, Finland and Carolina Säll, Novo Nordisk, Copenhagen, Denmark

coponnagon	Berman
9:00 - 9:30	Reflections on two decades of oligo ADME development Steve Hood, GSK, Stevenage, United Kingdom
9:30 - 10:00	Can we utilize a small molecule strategy when developing therapeutic peptides? Carolina Säll, Novo Nordisk, Copenhagen, Denmark
10:00 - 10:15	Relative and absolute bioavailability study of NXT007, a novel haemophilia A treatment, confirms patient flexibility between different injection sites (Abstract O017) Marion Anliker-Ort, F. Hoffmann-La Roche AG, Basel, Switzerland
10:15 - 10:30	Ex vivo pembrolizumab pharmacology for personalized PD-1 inhibitor therapy reveals a critical gap between receptor occupancy and T cell functionality (Abstract 0018) Judith Verdonk, Radboudume, Niimeaen, The Netherlands

Session C4: Neurodegenerative diseases (Small Hall)

Chairs: Mikko Airayaara, University of Helsinki, Helsinki, Finland and Dominiaue Deplanaue, University of Lille, Lille,

France	Allavadia, university of Heisitiki, Heisitiki, Hilliana and Dominique Deplanque, university of Lille, Lille,
9:00 - 9:30	Intra-cerebral administration of an anaerobic form of dopamine in Parkinson's disease: from experimental models to clinical development David Devos, University of Lille, Lille, France
9:30 - 10:00	Parkinson's disease subtypes - does it impact pharmacological management? Filip Scheperjans, University of Helsinki, Helsinki, Finland
10:00 - 10:15	Increased mortality in dementia patients using inhaled anticholinergics- a nationwide register study from the Swedish registry on dementia/cognitive disorders, SveDem (Abstract 0019) Suzan Almayahi, Karolinska Institutet, Stockholm, Sweden
10:15 - 10:30	CSF exposure of HER-096, a subcutaneously administered CDNF-peptidomimetic developed for Parkinson's disease (Abstract 0020) Kira Holmström, Herantis Pharma, Espoo, Finland

10:30 - 11:00 | Refreshment Break (Catering areas on 1st and 2nd floor)



11:00 - 12:30 | Concurrent Sessions

Session A4: TDM: benefits and limitations (Small Hall)

Chairs: Erik Eliasson, Karolinska Institutet, Stockholm, Sweden and Pierre Marquet, University of Limoges, Limoges, France

11:00 - 11:30	The value of mycophenolate mofetil therapeutic drug monitoring for kidney transplant patients
	Pierre Marquet University of Limoges, Limoges, France

11:30 - 12:00 Antimicrobial TDM in the critically ill

Jason Roberts, University of Queensland, Brisbane, Australia

12:00 - 12:15 Contribution of the gut microbiome to tacrolimus metabolism – a randomized phase I crossover trial in healthy volunteers (Abstract 0021)

Katja Susanne Gümüs, Heidelberg University Hospital, Department of Clinical Pharmacology and Pharmacoepidemiology, Heidelberg, Germany

12:15 - 12:30 Model-informed precision dosing of busulfan for children and adults undergoing allogeneic

hematopoietic stem cell transplantation: a critical evaluation (Abstract O022)

Rashudy Mahomedradja, Amsterdam UMC, Alkmaar, the Netherlands

Session B5: Addressing unmet needs (Great Hall)

Chairs: Timo Myöhänen, University of Helsinki, Helsinki, Finland and Caridad Pontes, Universitat Autónoma de Barcelona, Barcelona, Spain

11:00 - 11:30	Where are we with the disease-modifying therapies for Parkinson's disease
	Timo Myöhänen, University of Helsinki, Helsinki, Finland

11:30 - 12:00 Model-informed drug development for rare diseases

Piet van der Graaf, University of Leiden, The Netherlands

12:00 - 12:15 GABAergic modulation in neuropathic pain patients: results of a randomized controlled trial with the a2-subunit preferring GABA modulator, N-desmethyl-clobazam (Abstract 0023)

Marie Besson, Geneva University Hospitals, Geneva, Switzerland

12:15 - 12:30 Accelerating access to innovative therapies: a retrospective analysis of the EMA PRIME

program (Abstract 0024)

Vanessa A. Prieto, Vall d'Hebron University Hospital (HUVH), Barcelona, Spain

Session C5: Chronic pulmonary diseases (Auditorium)

Chairs: Jukka Mäenpää, Astra Zeneca, Gothenburg, Sweden and Clive Page, King's College London, London, United Kingdom

11:00 - 11:30 Disease modifying treatments in early COPD

Rod Hughes, AstraZeneca, Cambridge, United Kingdom

11:30 - 12:00 Emerging drug targets in chronic pulmonary disease

Clive Page, King's College London, London, United Kingdom

12:00 - 12:15 Attitudes of patients with obstuctive pulmonary disease on the global warming impact

of inhalers (Abstract 0025)

Olga Sič, Department Of Pharmacology, Toxicology And Clinical Pharmacology, Faculty Of Medicine Novi Sad, University Of Novi Sad, Novi Sad, Serbia

12:15 - 12:30 Metformin as adjuvant therapy in pulmonary fibrosis: open label, randomised clinical trial (proof-

of-concept study) (Abstract O026)

Shivom Pratap, Aiims New Delhi, New Delhi, India

12:30 - 14:00 | Lunch and Poster Viewing

Lunch (Catering areas in 1st and 2nd floor)
Posters and Coffee (Poster areas 1st to 4th floor)

13:00 - 14:00 Presenters at posters P221-P245, P325-P357, P414-P429



14:00 - 15:30 pm | Concurrent Sessions

Industry Sponsored Session A5: Medbase Symposium - Decision support tools in pharmacotherapy (Great Hall) Chairs: Maija Kaukonen, Medbase, Turku, Finland and Kari Laine, Medbase, Turku, Finland

Cridiis. Maija K	aukonen, meabase, turko, tiniana ana kan Laine, meabase, turko, tiniana
14:00 - 14:30	Decision support systems in optimizing pharmacotherapy: Evidence, challenges, and future directions Ylva Böttiger, Linköping University, Linköping, Sweden
14:30 - 15:00	Transforming care through clinical decision support – the future is here Christoph U. Herborn, City Hospital Dessau, Dessau, Germany
15:00 - 15:15	Medbase solutions for decision-making tools in pharmacotherapy Maija Kaukonen, Medbase, Turku, Finland
15:15 - 15:30	Protocol for assessing drug interaction prevalence in Estonia through digital decision support

integration (Abstract O027) Jana Lass, Tartu University Hospital, Tartu, Estonia

Session B6: ADME biomarkers and extracellular vesicles: Phenotyping of drug metabolism, transport, and interactions (Auditorium)

Chairs: Anne Filppula, Åbo Akademi University, Turku, Finland and Julia Stingl, University Hospital Heidelberg, Heidelberg, Germany

14:00 - 14:30	Application of endogenous biomarkers and liquid biopsy in patients with renal impairment Alexandra Galetin, University of Manchester, Manchester, United Kingdom	
14:30 - 15:00	Phenotyping with biomarkers to model drug interactions Julia Stingl, University Hospital Heidelberg, Heidelberg, Germany	
15:00 - 15:15	Identification of endogenous substrates of ABC transporters using untargeted metabolomics (Abstract O028) Feng Deng, University of Helsinki, Helsinki, Finland	
15:15 - 15:30	Intra-individual and inter-individual expression of "major" and "minor" drug metabolizing enzymes along the length of the human intestine (Abstract O029) Stefan Oswald, Institute of Pharmacology and Toxicology, Rostock University Medical	

Session C6: Vascular diseases (Small Hall)

Center, Rostock, Germany

Chairs: Virpi Talman, University of Turku, Turku, Finland and Gerard Rongen, Radboud University Medical Center, Nijmegen, the Netherlands

14:00 - 14:30	Lipid-lowering therapies - what is on the horizon for triglycerides and Lp(a)? Giuseppe Danilo Norata, University of Milan, Milan, Italy	
14:30 - 15:00	Is there a holy grail of anticoagulation without increased bleeding? Riitta Lassila, University of Helsinki, Helsinki, Finland	
15:00 - 15:15	A three-step static mechanistic approach to predicting complex interaction signals of direct oral anticoagulants (Abstract O030) Mostafa Schaat, University of Turku, Turku, Finland	
15:15 - 15:30	The association of CYP3A4, CYP3A5, ABCG2 and SLCO1B1 variants with atorvastatin-related ADRs and therapy switching: PGx-CardioDrug data (Abstract 0031) Lana Ganoci, University of Zagreb School of Medicine, Zagreb, Croatia	

15:30 - 16:00 | Refreshment Break (Catering areas on 1st and 2nd floor)

16:00 - 17:00 | EACPT General Assembly (Great Hall)

Chairs: EACPT Chairperson Gerard Rongen, University of Nijmegen, Nijmegen, the Netherlands and EACPT Chairperson-elect Janne Backman, University of Helsinki, Helsinki, Finland EACPT members (those affiliated with a national member society) are welcome

Report from the Chair (Gerard Rongen)
Report from the Treasurer (Julia Stingl)

Reports on activities of EACPT Working Groups

EACPT meeting 2027 Lille (Dominique Deplanque)

Future perspectives (Chair 2025-2027 Janne Backman)



17:00 - 18:30 | Concurrent Sessions

Sponsored Session: BCPT Nordic Symposium - Translational methods in drug metabolism and toxicity (Great Hall) Chairs, Aleksi Tornio, University of Turku, Turku, Finland and Ulf Simonsen, Aarhus University, Aarhus, Denmark		
17:00 - 17:30	Use of an in vivo like hepatic 3D spheroid model to study drug metabolism, drug hepatotoxicity, liver regeneration, hepatitis and MASH Magnus Ingelman-Sundberg, Karolinska Institutet, Stockholm, Sweden	
17:30 - 18:00	Translational aspects of biomarkers in chemotherapy-induced peripheral neuropathy Tore B. Stage, University of Southern Denmark, Odense, Denmark	
18:00 -18:15	Grapefruit juice inhibits CYP2B6, CYP2C9, CYP2C19 and CYP3A4 while lingonberry powder does not affect major CYP enzymes in humans (Abstract O032) Laura Aurinsalo, University of Helsinki and Helsinki University Hospital, Helsinki, Finland	
18:15 - 18:30	Non-targeted metabolomics for the identification of plasma metabolites associated with breast cancer resistance protein function (Abstract 0033) Kreetta Hämäläinen, University of Helsinki, Helsinki, Finland	

EASLDHILI & IUPHAR Session B7: Drug induced liver injury - Current topics (Auditorium)

Chairs: Caroline Samer, University of Geneva, Geneva, Switzerland and M Isabel Lucena, University of Malaga, Malaga, Spain

Maiaga, spairi	
17:00 - 17:30	Pharmacogenomics in DILI: A pathway to personalized precision medicine Ann Daly, University of Newcastle, Newcastle, United Kingdom
17:30 - 18:00	Design, endpoints and challenges in conducting randomized clinical trials in DILI Yimin Mao, Shanghai Jiao Tong University, Shanghai, China
18:00 - 18:15	Hepatic zonal distribution of OATP1B transporters and CYP enzymes affects simulated intracellular unbound concentrations of repaglinide and coproporphyrin I (Abstract O034) Marie-Noëlle Paludetto, University of Manchester, Centre For Applied Pharmacokinetic Research, Manchester, United Kingdom
18:15 - 18:30	Liver-derived extracellular vesicles for multi-omics analysis of drug metabolism and liver disease (Abstract 0035) Natalie Widmann, Dr. Margarete Fischer-bosch Institute Of Clinical Pharmacology, Stuttgart, Germany

Workshop on clinical pharmacology for teachers (Education Working Group) (Speaker ready room) Chairs: Joost Piët, Amsterdam UMC, Amsterdam, the Netherlands

17:00 - 18:30 Clinical Pharmacology and Therapeutics Teach the Teacher (CP4T) workshop:
How to set up a student-assistant system for CPT education
Joost Piët, Amsterdam UMC, Amsterdam, the Netherlands

17:00 - 18:30 | EACPT Council Meeting (for Councillors only) (Consistorium)

Chairs: EACPT Chairperson Gerard Rongen, University of Nijmegen, Nijmegen, the Netherlands and EACPT Chairperson-elect Janne Backman, University of Helsinki, Helsinki, Finland

19:15 - | Transportation to the Congress Dinner Restaurant (buses will leave from Senate Square starting at 19:15)

20:00 - | EACPT Congress Dinner at Restaurant Kalastajatorppa (separate ticket required)



TUESDAY, 1 JULY

8:30 - 9:25 | Workshops

Workshop 1 - KSCPT and EACPT Workshop 1: Model-informed precision dosing in pediatrics – Focus on cytotoxic agents (Small Hall)

Chairs: In-Jin Jang, Seoul National University Hospital, Seoul, Korea and Marja-Liisa Dahl, Karolinska Institute, Stockholm, Sweden

8:30 - 8:45	The long journey to develop Model-Informed Precision Dosing of Busulfan in Korean pediatric patients SeungHwan Lee, Seoul National University Hospital, Seoul, Korea
8:50 - 9:05	Multi-center Studies on Busulfan Precision Dosing in Pediatric Patients Eline Muilwijk, Prinses Máxima Centrum, Utrecht, The Netherlands
9:10 - 9:25	Carboplatin TDM in childhood cancer patients Gareth Veal, Newcastle University, Newcastle upon Tyne, United Kingdom

EUFEMED Workshop 2: Is there a need for more diversity in clinical drug development: Focus on early clinical trials. (Great Hall)

Chairs: Jan de Hoon, University & University Hospitals of Leuven, Leuven, Belgium

8:30 - 8:45	The importance of diversity in global drug development: an overview Yves Donazzolo, Eurofins, Lyon, France
8:45 - 9:05	Diversity in First-in-Human clinical trials: did the healthy volunteer evolve over the last 10 years? Thomas Lodeweyckx, SGS, Antwerp, Belgium
9:05 - 9:25	Diversity in early-phase clinical trials: when to include patients? Jan de Hoon, University & University Hospitals of Leuven, Leuven, Belgium

"Meet the Editors" Workshop 3 (Auditorium)

Chairs: Annikka Kalliokoski, Duodecim Medical Publications Ltd, Helsinki, Finland and Thomas Griesbacher, Medical University of Graz, Graz, Austria

8:30 - 9:25 Presenters/Panelists

Ulf Simonsen, Editor-in-Chief, Basic & Clinical Pharmacology & Toxicology Ann Daly, Senior Editor, British Journal of Clinical Pharmacology Piet van der Graaf, Editor-in-Chief, Clinical Pharmacology & Therapeutics Uwe Fuhr, Managing Editor, European Journal of Clinical Pharmacology

9:30 - 11:00 | Concurrent Sessions

Session A6: Pharmacoeconomics: economic aspects of pharmacotherapy (Small Hall)

Chairs: Miia Turpeinen, University of Oulu, Oulu, Finland and Dinko Vitezic, University of Rijeka, Rijeka, Croatia

9:30 - 10:00

Health Technology Assessment (HTA): Decisions on treatment efficiency guided by clinical judgement and pharmacoeconomics
David Webb, University of Edinburgh, Edinburgh, United Kingdom

10:00 - 10:30

Innovative cost-sharing models
Zoltan Kalo, Semmelweis University, Budapest, Hungary

Pharmacoeconomic evidence for disease-modifying therapies in spinal muscular atrophy:
experience from systematic and real-world data analyses (Abstract O036)
Andrej Belančić, Clinical Hospital Centre Rijeka & University of Rijeka, Faculty of Medicine, Rijeka, Croatia

10:45 - 11:00

Deprescribing of high dose proton pump inhibitors (PPI's) in an acute medical unit at NHS
University Hospitals of Liverpool Group (Abstract O037)

Rebecca Kuruvilla, NHS University Hospitals of Liverpool Group, Liverpool, United Kingdom



Session B8: Using routinely collected data to inform clinical pharmacology (Auditorium)

Chairs: Aleksi Tornio, University of Turku, Turku, Finland and Caridad Pontes, Universitat Autónoma de Barcelona, Barcelona, Spain

9:30 - 10:00	Advances in pharmacoepidemiological analyses of real-world data Daniel Prieto-Alhambra, University of Oxford, Oxford, United Kingdom	
10:00 - 10:30	Strategic view on utilizing real-world data during drug development Susana Perez-Gutthann, RTI Health Solutions, Barcelona, Catalonia, Spain	
10:30 - 10:45	Pseudo-worsening of renal function due to inhibition of renal creatinine secretion by oral antitumor therapeutics – a real-world data analysis (Abstract O038) Michael I. Sponfeldner, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany	
10:45 - 11:00	Using pharmacovigilance data for signal detection of breast cancer resistance protein- mediated drug interactions (Abstract 0039) Ronja Levomäki, Åbo Akademi University, Turku, Finland	

Session C7: Global infectious disease threats (Great Hall)

Chairs: Asko Järvinen, Helsinki University Hospital, Helsinki, Finland and Markus Zeitlinger, Medical University of Vienna, Vienna, Austria

9:30 - 10:00	New drugs against multi-drug resistant (MDR) gram negative bacteria - are we loosing the battle against the silent pandemia Günther Weiss, Medical University of Innsbruck, Innsbruck, Austria
10:00 - 10:30	New vaccine technologies as a response to Covid-19 and other infectious threats Hanna Nohynek, Chair, Strategic Advisory Group of Experts on Immunization (SAGE),WHO, Finland
10:30 - 10:45	Association of vancomycin pharmacokinetic/pharmacodynamic parameters with clinical outcomes in patients with enterococcal bacteremia: a cohort study (Abstract O040) Eda Kübra Sel, Dokuz Eylul University Faculty of Medicine Department of Medical Pharmacology, İzmir, Türkiye
10:45 - 11:00	Genome-wide association study on inflammatory neuropathies and SARS-CoV2 vaccines (Abstract 0041) Ilma Bertulyte, Department Of Medical Sciences, Clinical Pharmacology, Uppsala University,

11:00 - 11:20 | Refreshment Break (Catering areas on 1st and 2nd floor)

11:20 - 12:00 | Keynote Lecture 3 (Great Hall)

Chair: Gerard Rongen, University of Nijmegen, Nijmegen, the Netherlands

No time to lose: From virus hunting to health politics

Uppsala, Sweden

Peter Piot, London School of Hygiene & Tropical Medicine, London, United Kingdom

12:30 - 13:30 Presenters at posters P246-P270, P358-391, P430-P446

13:30 - 15:00 | Concurrent Sessions

ESPT & IUPHAR Session A7: Pharmacogenomics - challenges for implementation in different medical specialties (Great Hall)

Chairs: Andrew Somogyi, University of Adelaide, Australia and Ann Daly, University of Newcastle, Newcastle, United Kingdom

13:30 - 14:00	Implementing pharmacogenomics in psychiatry Elvira Bramon, University College London, London, United Kingdom
14:00 - 14:30	Implementing pharmacogenomics in oncology Matthias Schwab, Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
14:30 - 14:45	Description of the prevalence of actionable pharmacogenetic variants in the Montreal Heart Institute Hospital Cohort (Abstract 0042) Marc-Olivier Pilon, Université de Montréal, Montréal, Canada



14:45 - 15:00

14:45 - 15:00 Pharmacogenetics of repaglinide, gemfibrozil, and their interaction: effects of SLCO1 and CYP2C8 variants (Abstract 0043)

Anssi Mykkänen, University of Helsinki, Helsinki, Finland

Session B9: Advances in clinical trials methodology (Small Hall)

Chairs: Maija Kaukonen, Medbase, Turku, Finland and Florian Naudet, University of Rennes, Rennes, France

13:30 - 14:00

Routinely collected data (previously named as Real-World Evidence, RWE) integration in clinical trials

Lars G. Hemkens, University of Basel, Basel, Switzerland

14:00 - 14:30

Innovative trial designs: Adaptive and platform trials

Mireille Muller, Novartis, Basel, Switzerland

14:30 - 14:45

Personalized n-of-1 trials for statin intolerance (Abstract 0044)

Michael Andersen, Department of Clinical Pharmacology, Copenhagen University

Hospital - Bispebjerg, Copenhagen, Denmark

Pharmacokinetics and pharmacodynamics of AZD7798, a depleting antibody targeting CCR9 +T cells in healthy participants and patients with Crohn's disease (Abstract 0045)

Anna Lundahl, Astrazeneca, Gothenburg, Sweden

Session C8: New strategies in treatment of cancer (Auditorium)

Chairs: Olli Tenhunen, Finnish Medicines Agency Fimea and Oulu University Hospital, Oulu, Finland and Troels K. Beramann, University of Southern Denmark, Odense, Denmark

	,,
13:30 - 14:00	Repurposing of anti-cancer medicines Kimmo Porkka, University of Helsinki, Helsinki, Finland
14:00 - 14:30	Patient reported outcomes in cancer drug development Sigrid Klaar, NDA Group - SSI Strategy, Uppsala, Sweden
14:30 - 14:45	Impact of thiazide and fluoropyrimidine interaction on myelotoxicity and other adverse events: a retrospective cohort study (Abstract 0047) Gerard Ronda Roca, University Hospital Puerta de Hierro Majadahonda, Majadahonda (Madrid), Spain

15:00 - 16:00 | Closing Session and Farewells (Great Hall)

Awards and closing ceremony

Chairs: EACPT Chairperson Janne Backman, University of Helsinki, Helsinki, Finland, and EACPT Past-Chair Gerard Rongen, University of Nijmegen, Nijmegen, the Netherlands

Announcement of the 2025 EACPT Scientific Award, followed by the awardee's presentation Poster/Abstract presentation awards
Greetings from EACPT
Future Congresses
Closing words by the EACPT2025 Chairs



Science to Practice

Medbase brings together all clinically relevant areas of drug safety, grounded in the latest scientific evidence.

Our user-friendly solutions – available in over a dozen languages – support clinical decision-making and drive safer, more effective patient care.

Minxbase

Drug-drug interactions

gravbase

Drug treatment during pregnancy

xreactbase

Cross-hyper-sensitivities of drugs

M dosebase

Drug dosing, indications, contraindications

www.medbase.fi

riskbase

Adverse drug reactions

Nactbase

Drug treatment while breastfeeding

heparbase

Drug treatment in hepatic impairment

natural medicines

renbase

Drug treatment in renal failure

N pgxbase

Drug & dose according to pharmacogenetic profile

Come meet us at Stand #18





Conference venue

The Congress will take place at the University of Helsinki Main Building and City Centre Campus. The Main Building (Fabianinkatu 33, 00170 Helsinki) is located in the very heart of Helsinki, a short walk (650 meters) from the Central Railway Station, and with excellent connections by tram, metro and bus.

The airport train takes you to Helsinki city center in 30 minutes, making the venue extremely accessible for international delegates travelling from and to global destinations.

Parking near the Congress Venue: Europark P-Kluuvi (Fabianinkatu 27), and Aimo Park Kasarmitori (Fabianinkatu 17) are the nearest parking houses, both subject to a fee. Moreover, street parking is possible near the Congress Venue.

Entrance and Registration Desk

Entrance to the Congress Venue is from Fabianinkatu 33. EACPT2025 Congress Registration Desk will be located in the 1st floor Entrance Hall, right next to the entrance.

Opening Hours:

Saturday 28 June	18:00-19:45
Sunday 29 June	07:30-19:00
Monday 30 June	07:30-19:00
Tuesday 1 July	07:30-15:00

Congress name badges will be distributed at the registration desk in alphabetical order according to your last name (as given on the registration form).

Please note that the registration desk may be busy on Sunday right before the program starts, so it is advisable to arrive early for registration or to register on Saturday.

Participants who have purchased tickets for the Congress Dinner or Swim and Sauna at Allas Pool will get tickets for these events with their name badge.

Congress Venue and Accessibility

This page provides information on the EACPT2025 congress facilities and accessibility of the venue.

Luggage storing

There is a guarded luggage area for the congress guests to use specifically for larger luggage pieces on Tuesday 1 July, open from 8:00 to 17:00. Smaller items can be stored in lockers close to the Registration desk. Please follow the signage or consult the Registration desk.

Lost & Found

Lost items can be returned to registration desk. Any inquiries regarding lost items can be done at the registration desk during the congress days.

Photography


Kindly note that official photos will be taken throughout the congress days and the social events.



Photo: University of Helsinki, Linda Tammisto




Conference venue, floor plan





EXHIBITION



Exhibitors

- 1 Shimadzu
- 2 Fortrea
- 3 Certara
- 4 University of Turku (Bioanalytical Laboratory & TCDM)
- 6 British Pharmacological Society
- 9 WCP2026
- 11 Duodecim Publication
- 12 EACPT

- 14 Basic & Clinical Pharmacology & Toxicology
- 18 Medbase



Poster exhibition

To familiarize yourself with the posters, you can browse the **EACPT abstract book** for the abstracts. Additionally, abstracts can be accessed via the Congress App by searching for the presenter's name, for example, under each session in the Program.

Posters will be displayed on floors 1–4 throughout the Congress. Regular posters (category P) have been allocated to floors 2–4 based on their topics, while 20 trainee posters have been selected for an awards category (A) and will be displayed on floor 1. The floor is indicated by the number (see floor plan in the App or PDF Program): 1st floor (A101-), 2nd floor (P201-), 3rd floor (P301-) and 4th floor (P401-).

The Congress Program includes dedicated times when poster presenters will be available at their posters to discuss their work with attendees:

Date and time	1st floor	2nd floor	3rd floor	4th floor
Sunday 29 June from 13:00 to 14:00		P201-P220	P301-P324	P401-P413
Sunday 29 June from 13:15 to 14:00	A101-A120			
Monday 30 June from 13:00 to 14:00		P221-P245	P325-P357	P414-P429
Tuesday 1 July from 12:30 to 13:30		P246-P270	P358-P391	P430-P446

Poster presenters are expected to hang their posters on Sunday 29 June between 8:00 and 12:00.

The posters should remain on the exhibition boards until the end of the Congress. Thereafter, the presenters are expected to take them down. Please be advised that if your poster is not removed before 16:30 on Tuesday 1 July, it will be taken down and disposed of.



Social program

SATURDAY, 28 JUNE

Pre-meeting and dinner for early-career researchers

- WHEN: At 16:00-23:00
- WHERE: Solo Sokos Hotel Helsinki, Blomstedt Hall, Kluuvikatu 8, 00100 Helsinki
- WHY: Foster collaboration and mentorship under the theme "Career Development". Later in the evening a warm-hearted dinner is served

SUNDAY, 29 JUNE

Opening ceremony and Reception at the University of Helsinki

- WHEN: Opening ceremony at 19:30-20:00, Reception at the University of Helsinki 20:00-21:00
- WHERE: University of Helsinki Main Building, Great Hall, Fabianinkatu 33, 00170 Helsinki
- WHY: Time to network and mingle. Small snacks available after the program.
- NOTE: The reception is free of charge for registered participants but pre-registration is mandatory.

Swim and sauna under the midnight sun (Allas Pool)

- WHEN: 21:00-23:00, doors open at 21:00.
- WHERE: Allas Pool, Katajanokanlaituri 2a, 00160 Helsinki
- WHAT TO BRING: Your Allas Pool ticket and own swim suit
- PROVIDED: Towel and drink coupon at the entrance



Social event venue Allas Sea Pool. Photo: Allas Sea Pool/Helsinki Partners



MONDAY, 30 JUNE

EACPT early morning activities (run, walk or yoga)

- WHEN: At 6:40-7:40
- WHERE: Helsinki City Centre (exact starting points to be announced)
- WHY: Get an energy boost for the second congress day
 - Yoga: Meeting point at the Unisport Kluuvi entrance on Fabianinkatu 20 (opposite the main entrance of the congress venue) at 6:30. Yoga begins 6:40.
 - Running/walking: Meeting point Senate Square at 6:35. Running/walking start 6:40. Group leaders will be guiding the route. Information about routes will be provided later.
 - Yoga and Running/walking: Shower area and lockers on Fabianinkatu 20 (Yoga meeting point).

Congress Dinner

- WHEN: At 20:00-23:30
- WHERE: Hilton Helsinki Kalastajatorppa, 'Round Room' (Kalastajatorpantie 1, 00330 Helsinki)
- WHAT TO BRING: Your Dinner ticket

Bus transportation (included)

Senate Square (next to Congress venue) – Kalastajatorppa, Round Room

Departures starting at 19:15

Kalastajatorppa, 'Round Room' – Senate Square

Departures 22:30 | 22:45 | 23:00 | 23:15 | 23:30

Please arrive at the departure point on time if you wish to use the arranged transportation.



Restaurant Kalastajatorppa, Round Room





Platinum sponsors





Gold sponsors





Silver sponsors









































